These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 38786070)

  • 41. Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment.
    Dobie G
    Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modeling the public health impact of voxelotor in the management of sickle cell disease in France.
    Galacteros F; Ethgen O; Beillat M
    PLoS One; 2023; 18(9):e0291211. PubMed ID: 37703228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Revolutionising healing: Gene Editing's breakthrough against sickle cell disease.
    Dimitrievska M; Bansal D; Vitale M; Strouboulis J; Miccio A; Nicolaides KH; El Hoss S; Shangaris P; Jacków-Malinowska J
    Blood Rev; 2024 May; 65():101185. PubMed ID: 38493007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sickle cell diseases: What can nuclear medicine offer?
    Niccoli Asabella A; Altini C; Nappi AG; Lavelli V; Ferrari C; Marzullo A; Loiodice A; Rubini G
    Hell J Nucl Med; 2019; 22(1):2-3. PubMed ID: 30843001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A landscape analysis and discussion of value of gene therapies for sickle cell disease.
    Quach D; Jiao B; Basu A; Bender MA; Hankins J; Ramsey S; Devine B
    Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):891-911. PubMed ID: 35363602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now?
    Tanhehco YC; Bhatia M
    Curr Opin Hematol; 2019 Nov; 26(6):448-452. PubMed ID: 31483336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hope on the Horizon: New and Future Therapies for Sickle Cell Disease.
    Kuriri FA
    J Clin Med; 2023 Sep; 12(17):. PubMed ID: 37685759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review/overview of pain in sickle cell disease.
    Ballas SK; Darbari DS
    Complement Ther Med; 2020 Mar; 49():102327. PubMed ID: 32147066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hematopoietic stem cell transplantation for sickle cell disease: state of the science.
    Talano JA; Cairo MS
    Eur J Haematol; 2015 May; 94(5):391-9. PubMed ID: 25200500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sickle Cell Disease: From Genetics to Curative Approaches.
    Hardouin G; Magrin E; Corsia A; Cavazzana M; Miccio A; Semeraro M
    Annu Rev Genomics Hum Genet; 2023 Aug; 24():255-275. PubMed ID: 37624668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene Therapies for Sickle Cell Disease.
    Weaver SB; Singh D; Wilson KM
    J Pharm Technol; 2024 Oct; 40(5):236-247. PubMed ID: 39391326
    [No Abstract]   [Full Text] [Related]  

  • 56. Genetic Therapies for Sickle Cell Disease.
    Jayavaradhan R; Malik P
    Pediatr Clin North Am; 2018 Jun; 65(3):465-480. PubMed ID: 29803277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic therapies for sickle cell disease.
    Esrick EB; Bauer DE
    Semin Hematol; 2018 Apr; 55(2):76-86. PubMed ID: 29958563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.